Systematic Review on 1,2,3-Oxadiazoles, 1,2,4-Oxadiazoles, and 1,2,5-Oxadiazoles in the Antimycobacterial Drug Discovery

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2025-01-23 DOI:10.1002/cmdc.202400971

Dr. Marta Kučerová-Chlupáčová

引用次数: 0

Abstract

Tuberculosis remains a leading global health threat, exacerbated by the emergence of multi-drug-resistant strains. The search for novel therapeutic agents is critical in addressing this challenge. This review systematically summarizes the potential of oxadiazole derivatives as promising candidates in antimycobacterial drug discovery. We focus on various classes of oxadiazoles, especially 1,2,3-oxadiazoles, 1,2,4-oxadiazoles, and 1,2,5-s in structure-activity relationship studies are discussed, emphasizing the mechanisms of antimycobacterial action. Additionally, the synergistic potential of 1,2,4-oxadiazoles in enhancing the efficacy of existing tuberculosis treatment with ethionamide is also discussed. By integrating insights from recent research, this review aims to provide a comprehensive overview of the role of oxadiazoles in the fight against tuberculosis, paving the way for future investigations and the development of effective therapeutic strategies.

Abstract Image

查看原文本刊更多论文

1,2,3-恶二唑、1,2,4-恶二唑和1,2,5-恶二唑在抗细菌药物发现中的系统评价。

结核病仍然是全球主要的健康威胁，多药耐药菌株的出现加剧了这一威胁。寻找新的治疗药物是解决这一挑战的关键。本文系统地综述了恶二唑衍生物在抗细菌药物开发中的潜力。我们重点研究了各种类型的恶二唑，特别是1,2,3-恶二唑、1,2,4-恶二唑和1,2,5-恶二唑，重点介绍了它们的结构多样性和生物活性。本文讨论了结构-活性关系研究的最新进展，重点介绍了抗真菌作用的机制。此外，还讨论了1,2,4-恶二唑在提高乙硫酰胺治疗现有结核病疗效方面的协同潜力。通过整合近期研究的见解，本综述旨在全面概述恶二唑在对抗结核病中的作用，为未来的研究和有效治疗策略的发展铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.